Heart failure & cardiomyopathies
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry
Authors' conclusion
In this large, real-world HF cohort with T2DM, ∼1/3 of patients were eligible for sotagliflozin in the literal and ∼2/3 of patients in the pragmatic scenario. Eligible patients had more severe HF and higher event rates, in particular CV and HF events.
Study context
- Population
- Inpatients with T2DM and recent worsening heart failure (HF) stabilized after HF hospitalization, Swedish HF Registry
- Participants
- 5,453 inpatients
- Exposure
- Eligible vs non-eligible for sotagliflozin by SOLOIST-WHF criteria
- Outcome
- Eligibility for sotagliflozin by SOLOIST-WHF criteria (literal and pragmatic scenarios)
Methodological detailsSwedish HF Registry
- Swedish HF Registry
Main finding
As reported in the abstract
Eligibility for sotagliflozin
- Eligibility, literal scenario (all inclusion/exclusion criteria), overall
- 27.2%
- Eligibility, literal, HFrEF
- 32.4%
- Eligibility, literal, HFmrEF
- 24.7%
- Eligibility, literal, HFpEF
- 19.7%
- Eligibility, pragmatic scenario (only criteria likely to influence treatment decisions), overall
- 62.8%
- Eligibility, pragmatic, HFrEF
- 69.1%
- Eligibility, pragmatic, HFmrEF
- 60.3%
- Eligibility, pragmatic, HFpEF
- 53.4%
Observational data: associations, not effects.
Further findings
| Outcome | Eligible | Non-eligible |
|---|---|---|
| Event rates, eligible vs non-eligible | ||
| All-cause death | 30.8 per 100 patient-years | 27.2 per 100 patient-years |
| CV death | 19.1 | 16.6 |
| HF hospitalization | 36.7 | 24.0 |
Event rates, eligible vs non-eligible
- Eligible patients had more severe HF, higher cardiovascular (CV) comorbidity burden and higher use of HF treatments
Original publication
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry. Eur Heart J Cardiovasc Pharmacother. Published 30 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →